Abbott acquires Aventis’ Mavik
Abbott Labs acquires full manufacturing and commercial rights to Aventis' cardiovascular drugs Mavik and Tarka for $300 mil. plus royalties. Abbott already holds marketing rights to Mavik (trandolapril) and Tarka (trandolapril/verapamil) in the U.S. and other countries under a 1991 licensing deal. Aventis will retain rights to the products in Japan. Combined global sales topped $200 mil. in 2003; Abbott believes sales of the two drugs could eventually reach $700 mil. The divestiture is not related to the Sanofi merger, Aventis says...
You may also be interested in...
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
The ongoing availability of many medical devices in Switzerland is threatened even more severely than in the EU. Medtech Insight spoke to two key life science experts to understand why this is and to hear the solutions they are proposing.